Jane Street’s Standard BioTools LAB Stock Holding History

Jane Street’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,400	Closed	-$13.3K	–	12343
2025 Q4	$13.3K	Buy	+10,400	New	+$14K	﹤0.01%	10798
2022 Q1	–	Sell	-22,200	Closed	-$87K	–	10694
2021 Q4	$87K	Sell	22,200 -8,400	-27%	-$39.3K	﹤0.01%	9310
2021 Q3	$202K	Sell	30,600 -9,200	-23%	-$60.5K	﹤0.01%	8823
2021 Q2	$245K	Sell	39,800 -20,100	-34%	-$107K	﹤0.01%	8499
2021 Q1	$271K	Sell	59,900 -22,400	-27%	-$123K	﹤0.01%	7841
2020 Q4	$494K	Sell	82,300 -329,900	-80%	-$2.17M	﹤0.01%	5771
2020 Q3	$3.06M	Buy	+412,200	New	+$2.85M	﹤0.01%	2415

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Jane Street's LAB Position: Q1 2026 in Review

Jane Street sold out of Standard BioTools (LAB) in Q1 2026, closing a stake of 769,231 shares — an estimated $985K sold.

Jane Street first reported a position in LAB in Q1 2014 and held it in 26 quarters. The position peaked at $3.75M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

Jane Street reported no remaining Standard BioTools position as of Q1 2026 after selling out during the quarter.
Jane Street sold 769,231 Standard BioTools shares in Q1 2026, an estimated $985K.
Jane Street first reported a position in Standard BioTools in Q1 2014 and held it in 26 quarters.
Jane Street's Standard BioTools position peaked at $3.75M in Q1 2024.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.